This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Fusion Pharmaceuticals Inc.. Active years: 2022.
Company Filing History:
Years Active: 2022
Title: Enza Piccolo: Innovator in Antibody Development
Introduction
Enza Piccolo is a prominent inventor based in Lanciano, Italy. She has made significant contributions to the field of biotechnology, particularly in the development of antibodies that target specific cell surface antigens associated with tumors. Her work is crucial in advancing cancer treatment methodologies.
Latest Patents
Enza Piccolo holds a patent for an Endosialin-binding antibody. This innovative antibody specifically recognizes and binds to Endosialin, a cell surface antigen characteristic of tumor pericytes and cells of tumor stroma. The antibody has the ability to become internalized in Endosialin-expressing cells and block the activation of MAPK in PDGF-stimulated human pericytes. Additionally, it can inhibit angiogenesis induced by LGALS3BP, a known Endosialin interactor, and effectively inhibit tumor growth both alone and in combination with a humanized antibody against LGALS3BP in human osteosarcoma xenografts. Furthermore, when conjugated with a duocarmycin derivative, the resulting antibody-drug conjugate displays potent in vitro tumor cell cytotoxicity and effective antitumor efficacy in vivo.
Career Highlights
Enza Piccolo is currently associated with Fusion Pharmaceuticals Inc., where she continues to innovate in the field of antibody development. Her work has garnered attention for its potential impact on cancer therapies.
Collaborations
Enza collaborates with notable colleagues such as Gianluca Sala and Stefano Iacobelli, contributing to a dynamic research environment that fosters innovation.
Conclusion
Enza Piccolo's contributions to antibody development represent a significant advancement in cancer treatment. Her innovative work continues to pave the way for new therapeutic strategies in oncology.